Eli Lilly Net Acquisitions/Divestitures 2010-2025 | LLY
Eli Lilly annual/quarterly net acquisitions/divestitures history and growth rate from 2010 to 2025. Net acquisitions/divestitures can be defined as the total change in cash resulting from both investments in businesses and sales of businesses or business segments.
- Eli Lilly net acquisitions/divestitures for the quarter ending March 31, 2025 were $0M, a 0% increase year-over-year.
- Eli Lilly net acquisitions/divestitures for the twelve months ending March 31, 2025 were $-2.843B, a 172.25% increase year-over-year.
- Eli Lilly annual net acquisitions/divestitures for 2024 were $-0.948B, a 9.25% decline from 2023.
- Eli Lilly annual net acquisitions/divestitures for 2023 were $-1.044B, a 219.16% increase from 2022.
- Eli Lilly annual net acquisitions/divestitures for 2022 were $-0.327B, a 56.22% decline from 2021.
Eli Lilly Annual Net Acquisitions/Divestitures
(Millions of US $) |
| 2024 |
$-948 |
| 2023 |
$-1,044 |
| 2022 |
$-327 |
| 2021 |
$-747 |
| 2020 |
$-849 |
| 2019 |
$-6,563 |
| 2018 |
$N/A |
| 2017 |
$-882 |
| 2016 |
$-45 |
| 2015 |
$-5,283 |
| 2014 |
$-551 |
| 2013 |
$-44 |
| 2012 |
$-199 |
| 2011 |
$-308 |
| 2010 |
$-609 |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$676.408B |
$45.043B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
